Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 194.77M +479.7% |
| Revenue (ttm) | 146.07M +0.6% |
| Net Income | -196.04M |
| EPS | -17.93 |
| Shares Out | 22.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,098 |
| Open | 8.66 |
| Previous Close | 8.66 |
| Day's Range | 8.50 - 8.93 |
| 52-Week Range | 3.65 - 10.99 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+85.19%) |
| Earnings Date | May 4, 2026 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KPTI stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 85.19% from the latest price.
News
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-br...
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.
Karyopharm Therapeutics Transcript: Study result
The phase III SENTRY trial showed Selinexor plus Ruxolitinib nearly doubled spleen response rates and demonstrated a promising overall survival benefit in JAK inhibitor-naive Myelofibrosis, with manageable safety and early signs of disease modification. Further regulatory engagement and data maturation are planned.
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
Karyopharm Therapeutics said on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a late‑stage trial in patients with a rare blood cancer, one of...
Karyopharm Announces $30 Million Private Placement with RA Capital
NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ente...
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubli...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...
Karyopharm Therapeutics Transcript: EGM 2026
A virtual special meeting was held to vote on increasing authorized shares and the potential adjournment for further proxy solicitation. Both proposals passed, with final results to be filed in a Form 8-K. No questions were raised by stockholders.
Karyopharm Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew modestly in 2025, with XPOVIO sales up and cost reductions improving operating loss. Pivotal phase 3 data in myelofibrosis is expected in March, with a strong commercial focus on this opportunity and a cash runway into Q2 2026.
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Reve...
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Preliminary...
Karyopharm Therapeutics Transcript: Baird's Biotech Discovery Series
Selinexor plus ruxolitinib shows strong efficacy and manageable safety in myelofibrosis, with phase III SENTRY results expected in March. The combination could address significant unmet needs, offering a potential new frontline standard and a major commercial opportunity.
Karyopharm to Participate in Baird's Biotech Discovery Series
NEWTON, Mass. , Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...
Karyopharm Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Selinexor, an oral Exportin-1 inhibitor, is expanding its reach in multiple myeloma and advancing in myelofibrosis and endometrial cancer, with pivotal phase III data expected in 2024 and 2026. Market potential is strong, supported by recent financial restructuring and robust clinical results.
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...
Karyopharm Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 13% year-over-year, driven by XPOVIO and milestone revenues. SENTRY Phase III trial in myelofibrosis completed enrollment, with top-line data expected March 2026. Financial flexibility was strengthened, supporting operations into Q2 2026.
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase ...
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility...
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the Third Quarter...
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
– Top-Line Results Anticipated in March 2026 – NEWTON, Mass. , Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel ca...
Karyopharm Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw solid commercial performance with XPOVIO net product revenue up 6% year-over-year and royalty revenue up 28%. Liquidity remains a concern due to an October debt maturity, but pivotal phase III trial readouts in myelofibrosis and endometrial cancer are on track for 2026.
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) ...
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass.